skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis

Clinical infectious diseases, 2022-06, Vol.76 (3), p.e938-e946 [Peer Reviewed Journal]

The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. ;The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022 ;ISSN: 1058-4838 ;EISSN: 1537-6591 ;DOI: 10.1093/cid/ciac528 ;PMID: 35767251

Full text available

Citations Cited by
  • Title:
    Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
  • Author: Padmapriyadarsini, Chandrasekaran ; Vohra, Vikram ; Bhatnagar, Anuj ; Solanki, Rajesh ; Sridhar, Rathinam ; Anande, Lalitkumar ; Muthuvijaylakshmi, M ; Bhatia, Miraa ; Jeyadeepa, Bharathi ; Taneja, Gaurav ; Balaji, S ; Shah, Prashant ; Saravanan, N ; Chauhan, Vijay ; Kumar, Hemanth ; Ponnuraja, Chinnayin ; Livchits, Viktoriya ; Bahl, Monica ; Alavadi, Umesh ; Sachdeva, K S ; Swaminathan, Soumya
  • Subjects: Major
  • Is Part Of: Clinical infectious diseases, 2022-06, Vol.76 (3), p.e938-e946
  • Description: Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain low globally. Availability of newer drugs has given scope to develop regimens that can be patient-friendly, less toxic, with improved outcomes. We proposed to determine the effectiveness of an entirely oral, short-course regimen with Bedaquiline and Delamanid in treating MDR-TB with additional resistance to fluoroquinolones (MDR-TBFQ+) or second-line injectable (MDR-TBSLI+). We prospectively determined the effectiveness and safety of combining two new drugs with two repurposed drugs - Bedaquiline, Delamanid, Linezolid, and Clofazimine for 24-36 weeks in adults with pulmonary MDR-TBFQ+ or/and MDR-TBSLI+. The primary outcome was a favorable response at end of treatment, defined as two consecutive negative cultures taken four weeks apart. The unfavorable outcomes included bacteriologic or clinical failure during treatment period. Of the 165 participants enrolled, 158 had MDR-TBFQ+. At the end of treatment, after excluding 12 patients due to baseline drug susceptibility and culture negatives, 139 of 153 patients (91%) had a favorable outcome. Fourteen patients (9%) had unfavorable outcomes: four deaths, seven treatment changes, two bacteriological failures, and one withdrawal. During treatment, 85 patients (52%) developed myelosuppression, 69 (42%) reported peripheral neuropathy, and none had QTc(F) prolongation >500msec. At 48 weeks of follow-up, 131 patients showed sustained treatment success with the resolution of adverse events in the majority. After 24-36 weeks of treatment, this regimen resulted in a satisfactory favorable outcome in pulmonary MDR-TB patients with additional drug resistance. Cardiotoxicity was minimal, and myelosuppression, while common, was detected early and treated successfully.
  • Publisher: United States: Oxford University Press
  • Language: English
  • Identifier: ISSN: 1058-4838
    EISSN: 1537-6591
    DOI: 10.1093/cid/ciac528
    PMID: 35767251
  • Source: Alma/SFX Local Collection
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait